108 related articles for article (PubMed ID: 19426777)
1. Dosing of antipsychotics in schizophrenia across the life-spectrum.
Uchida H; Mamo DC
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(6):917-20. PubMed ID: 19426777
[TBL] [Abstract][Full Text] [Related]
2. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan.
Uchida H; Suzuki T; Mamo DC; Mulsant BH; Tanabe A; Inagaki A; Watanabe K; Yagi G; Tomita M
Am J Geriatr Psychiatry; 2008 Jul; 16(7):584-93. PubMed ID: 18591578
[TBL] [Abstract][Full Text] [Related]
3. Strategies for dosing and switching antipsychotics for optimal clinical management.
Buckley PF; Correll CU
J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
[TBL] [Abstract][Full Text] [Related]
4. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
5. Dosing atypical antipsychotics.
Cutler A; Ball S; Stahl SM
CNS Spectr; 2008 May; 13(5 Suppl 9):1-16. PubMed ID: 18496483
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic.
Ereshefsky L
J Clin Psychiatry; 1999; 60 Suppl 10():20-30. PubMed ID: 10340684
[TBL] [Abstract][Full Text] [Related]
7. Drugs in development for the treatment of schizophrenia.
Emsley R
Expert Opin Investig Drugs; 2009 Aug; 18(8):1103-18. PubMed ID: 19589093
[TBL] [Abstract][Full Text] [Related]
8. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
Kane JM; Leucht S; Carpenter D; Docherty JP;
J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
[TBL] [Abstract][Full Text] [Related]
9. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
10. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
11. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
Miyamoto S; Duncan GE; Marx CE; Lieberman JA
Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
[TBL] [Abstract][Full Text] [Related]
12. Prescribing for inpatients with schizophrenia: an international multi-center comparative study.
Bitter I; Chou JC; Ungvari GS; Tang WK; Xiang Z; Iwanami A; Gaszner P
Pharmacopsychiatry; 2003 Jul; 36(4):143-9. PubMed ID: 12905100
[TBL] [Abstract][Full Text] [Related]
13. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
14. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
Arranz MJ; de Leon J
Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of antipsychotic drug-induced movement disorders.
Casey DE
J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109
[TBL] [Abstract][Full Text] [Related]
17. Recommendations from treatment guidelines for schizophrenia regarding monitoring of side effects of antipsychotics: brief review.
Kozumplik O; Uzun S
Psychiatr Danub; 2009 Mar; 21(1):95-8. PubMed ID: 19270630
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of clozapine versus other antipsychotics on clinical outcome and dopamine release in the brain.
Advokat C
Essent Psychopharmacol; 2005; 6(2):73-90. PubMed ID: 15765792
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
20. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
Turner MS; Stewart DW
J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
